Type of security: Fund
The data is delayed by 15 minutes.
Description: The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.
|High 52 week||122.16||Low 52 week||89.61||Last close||103.77||Last change||-0.64%|
|RSI||39.15||Average true range||2.42||Beta||0.99||Volume||1.25 M|
|Simple moving average 20 days||-1.64%||Simple moving average 50 days||-4.82%||Simple moving average 200 days||-5.74%|
|Performance Week||-1.17%||Performance Month||-1.3%||Performance Quart||-7.38%||Performance Half||-0.25%|
|Performance Year||-3.36%||Performance Year-to-date||7.61%||Volatility daily||1.35%||Volatility weekly||3.01%|
|Volatility monthly||6.17%||Volatility yearly||21.36%||Relative Volume||180.65%||Average Volume||2.72 M|
|New High||New Low|
|30-day SEC yield||Average market capitalization||Average weighted market capitalization||Forward P/E|
|Gross expense ratio||Index dividend yield||Median market cap||Number of holdings||0|
|Price to Book Value||9.9||Price to Earnings||40.91||Total expense ratio||0.48%||Total net assets||4.92 B|
|Weighted market capitalization|
|Total Expense Ratio||0,48|
|Number Of Holdings||n/a|
|Total Net Assets||4 915 409 116,00|
|Biogen Idec Inc||8,04|
|Gilead Sciences Inc||7,67|
|Alexion Pharmaceuticals Inc||6,78|
|Regeneron Pharmaceuticals Inc||4,04|
|Vertex Pharmaceuticals Inc||3,92|
|Biomarin Pharmaceutical Inc||2,36|
2019-06-21 09:15:01 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-06-21 07:31:00 | ContraVir's stock rockets off record low after 'positive feedback' on pre-IND for NASH
2019-06-17 13:31:00 | Adaptive Biotechnologies sets terms for IPO, to raise up to $212.5 million
2019-06-17 13:17:00 | Karuna Therapeutics sets IPO terms, to be valued at up to $363 million
2019-06-14 09:50:00 | Morphic Holding sets terms of IPO to raise up to $80 million
2019-06-13 07:27:00 | Provention Bio's stock surges after calling off public stock offering
2019-06-12 06:29:46 | Barclays Has New Plays for Healthcare Fans
2019-06-07 08:56:00 | Cancer genomics company Personalis expects to raise up to $107 million in IPO
2019-06-04 11:07:35 | Biotech Sector Could Enter Bear Market
2019-05-30 06:53:10 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-05-23 13:21:00 | Ideaya Biosciences' stock opened 40% above its IPO price, then pared most of its gains
2019-05-20 09:02:00 | Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days
2019-05-15 06:55:16 | Foamix FOMX: A Beaten-Down Biotech Stock That Looks Like a Bargain Now
2019-05-13 22:54:31 | Reaping the Benefits of In-Depth Knowledge of ETFs
2019-05-13 14:15:06 | FDA Issues Final Guidelines To Make Interchangeable Biosimilars More Easily Available
2019-05-09 07:46:00 | These 3 revolutionary genomics companies are changing lives for patients — and investors
2019-05-07 16:57:08 | Biotech ETFs in Focus on String of Q1 Earnings Beats
2019-05-02 13:21:00 | These 6 biotech stocks are promising takeover targets
2019-04-30 13:00:34 | Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates
2019-04-30 10:39:00 | Axcella Health sets IPO terms, which could value the biotech at up to $505.7 million
2019-04-26 14:01:00 | Gilead Stock Is Due for a Comeback, Analyst Says
2019-04-25 13:26:09 | Can Health Care Recover from Medicare for All?
2019-04-24 16:04:08 | Will Biotech ETFs Continue to Rally in Q1 Earnings?
2019-04-18 12:17:58 | Intuitive Surgical Stock Is Down but Not Out
2019-04-15 13:49:47 | ImmunoGen Stock Is in Trouble Going Into Earnings
2019-04-15 10:46:00 | Bio-Path's stock rockets after withdrawal of stock offering
2019-04-12 08:16:00 | Biotech company Axcella Health files for IPO
2019-04-12 07:23:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-04-10 16:44:08 | Global X Launches GNOM ETF to Tap Booming Genomics Space
2019-04-10 11:11:10 | Is AstraZeneca Stock Worth Buying Before Earnings?
2019-04-03 12:23:00 | Democrats, Republicans agree on legislation targeting drug prices
2019-04-03 07:44:00 | Advaxis' stock plummets after public offering prices at deep discount
2019-03-25 08:49:00 | 5 biotech stocks that could be the next big winners
2019-03-25 07:26:00 | Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge
2019-03-21 11:16:40 | Biotech Funds Could Generate Profitable Short Sales
2019-03-21 09:46:59 | Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial
2019-03-21 06:52:00 | Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role
2019-03-20 07:07:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-03-14 15:51:00 | Gilead Stock Could Surge to $84, Says Analyst